Novogen (NRT) subsidiary, Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the US Patent and Trademark Office has issued a new patent covering a number of the company’s isoflavone-based compounds, including lead oncology drug candidates ME-143 and ME-344, and their pharmaceutical compositions. The patent is estimated to provide protection until March 2027.
“This patent represents another important milestone in our efforts to develop our lead drug candidates into valuable treatment options for patients with cancer” said Daniel P Gold, PhD, President and Chief Executive Officer of Marshall Edwards. “Furthermore, this demonstrates our commitment to further strengthening the intellectual property portfolio we acquired earlier this year, which will be essential for partnering any of our drug candidates and enhancing shareholder value.”
Marshall Edwards completed the acquisition of its isoflavone-based intellectual property portfolio, including worldwide rights to lead oncology drug candidates ME-143 and ME-344, from Novogen Limited in May 2011. The portfolio now includes 11 issued US patents, at least 14 US patent applications, at least 40 issued foreign patents and at least 80 foreign patent applications. Marshall Edwards, Inc. is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The company’s lead programs focus on two families of small molecules that result in the inhibition of tumour cell metabolism. Novogen Limited (NRT) is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc.
http://www.traderdealer.com.au/Fundamentals/nrt
